What is Mapi Pharma?
Mapi Pharma is a clinical-stage pharmaceutical company headquartered in Ness Ziona, Israel, specializing in the development of advanced long-acting depot injectable therapies. The company's pipeline includes a lead product, Glatiramer Acetate Depot, aimed at treating multiple sclerosis, a condition with a substantial patient population. Mapi Pharma also focuses on other therapeutic areas, such as developing extended-release formulations for Pregabalin to manage neuropathic pain and treatments for schizophrenia. Operating fully integrated GMP manufacturing facilities, the company demonstrates a commitment to quality and end-to-end development capabilities.
How much funding has Mapi Pharma raised?
Mapi Pharma has raised a total of $10M across 1 funding round:
Share Placement
$10M
Share Placement (2015): $10M with participation from Shavit Capital
Key Investors in Mapi Pharma
Shavit Capital
Shavit Capital is an investment practice specializing in late-stage investments in Israeli and Israeli-related companies, managing over $500 million across five private equity funds. They focus on companies with proven technologies and strong management teams, providing substantial capital for growth through equity, mezzanine, or bridge rounds.
What's next for Mapi Pharma?
The recent major strategic investment signals a pivotal phase for Mapi Pharma, likely enabling the acceleration of its clinical development programs and the scaling of its manufacturing operations. This capital infusion is expected to support the advancement of its lead candidates through late-stage trials and towards potential commercialization. The company's focus on complex formulations and long-acting injectables positions it to address unmet medical needs in significant therapeutic markets, potentially leading to substantial growth and market penetration.
See full Mapi Pharma company page
